The group's principal activity is to develop pharmaceutical products for the biopharmaceutical industry based on new and proprietary oral drug delivery technologies. The primary oral drug delivery system of the company is the patented gastric retention system. The group also develops the reduced irritation system, which is designed to provide for significant reduction in local upper gastrointestinal irritation from the effects of certain drugs. The group develops proprietary products utilizing internal technology as well as in collaboration with pharmaceutical and biotechnology companies.the group operates solely in the domestic market.
